Patients whose ER-positive breast tumors had high levels of phosphorylation of ER-alpha serine-118-P had a significant recurrence-free survival while assigned to adjuvant tamoxifen.

Shi, L. et al.Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol. 27, 3423–3429 (2009).

Women with ER-positive breast cancer who experience a decline in mammographic density after the initiation of tamoxifen may have improved prognosis regardless of age, according to study findings ...

Gray said prior research has shown that 5 years of tamoxifen reduces breast cancer recurrence and mortality by approximately one-third over a 10- to 15-year period following diagnosis.

In the first cohort of 710 consecutive patients, overexpression of ER-α36 was associated with poorer disease-free survival (DFS) and disease-specific survival (DSS) in patients with ER-α66–positive ...

Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER)-positive patients. We have previously reported that hexamethylene bis-acetamide-inducible protein 1 (HEXIM1 ...

Study finds a more than four-fold increased risk of ER negative second cancers SEATTLE — Aug. 25, 2009 — While long-term tamoxifen use among breast cancer survivors decreases their risk of developing ...

Introduction. Tamoxifen is one of the most commonly used endocrine therapeutic agents for the treatment of estrogen receptor (ER)-positive breast cancer and is classified as a selective ER ...

SEATTLE — July 3, 2001 — A new study from the Fred Hutchinson Cancer Research Center confirms that tamoxifen use decreases the risk of a second breast cancer, but it also finds that the drug may cause ...

Doctors prescribe them to treat ER-positive breast cancer, either following tamoxifen treatment or by themselves. There are other hormone therapy drugs used to treat breast cancer, too.

Find patient medical information for Tamoxifen on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Purpose Recently, a 36-kDa variant of estrogen receptor α (ER-α66), ER-α36, has been identified and cloned. ER-α36 predominantly localizes on the plasma membrane and in the cytoplasm and mediates a ...